Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3

Status

Terminated 3Suspended 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Glioblastoma 2Sarcoma 1Neoplasms 1Meningioma 1Glioma 1Brain Neoplasms 1

Interventions

Cyclophosphamide 98pembrolizumab 87Gemcitabine 81Carboplatin 63fludarabine 62Nivolumab 57Cisplatin 54Paclitaxel 51Radiotherapy 50Docetaxel 50Rituximab 46Dexamethasone 42Lenalidomide 41Ipilimumab 38Azacitidine 35Etoposide 34Cytarabine 34Temozolomide 32Bevacizumab 32Radiation 29venetoclax 28Bortezomib 27Magnetic Resonance Spectroscopy 26Irinotecan 26atezolizumab 25Pemetrexed 25Oxaliplatin 24Capecitabine 24fludarabine phosphate 23Filgrastim 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Terminated × fluoromisonidazole × Clear all
NCT01246869 2024-10-01

Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water

University of Utah

Phase 1 Terminated
2 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Meningioma, Neoplasms

NCT03730077 2021-03-18

FMISO PET/CT Imaging Trial for Assessing Hypoxia in Soft Tissue Sarcomas

University of Pennsylvania

Phase 1 Terminated
5 enrolled
Sarcoma

Sarcoma

NCT03573986 2020-02-17

Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment

Abramson Cancer Center at Penn Medicine

Phase 1 Terminated
2 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡